PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展

许飞; 刘建军; 黄钢; 宋少莉; 许飞; 刘建军; 黄钢; 宋少莉

doi:10.3760/cma.j.issn.1673-4114.2016.01.008

[1]

Hielscher A, Gerecht S.Hypoxia and free radicals:Role in tumor progression and the use of engineering-based platforms to address these relationships[J].Free Radic Biol Med, 2015, 79:281-291.DOI:10.1016/j.freeradbiomed.2014.09.015.

[2]

Halmos GB, Bruine de Bruin L, Langendijk JA, et al.Head and neck tumor hypoxia imaging by ¹⁸F-fluoroazomycin-arabinoside(¹⁸F-FAZA)-PET:a review[J].Clin Nucl Med, 2014, 39(1):44-48.DOI:10.1097/RLU.0000000000000286.

[3]

Padhani AR.Where are we with imaging oxygenation in human tumours?[J].Cancer Imaging, 2005, 5:128-130.DOI:10.1102/1470-7330.2005.0103.

[4]

Vaupel P, Mayer A.The clinical importance of assessing tumor hypoxia:Relationship of tumor hypoxia to prognosis and therapeutic opportunities[J].Antioxid Redox Signal, 2015, 22(10):878-880.DOI:10.1089/ars.2014.6155.

[5]

Carreau A, El Hafny-Rahbi B, Matejuk A, et al.Why is the partial oxygen pressure of human tissues a crucial parameter?Small molecules and hypoxia[J].J Cell Mol Med, 2011, 15(6):1239-1253.DOI:10.1111/j.1582-4934.2011.01258.x.

[6]

Bourgeois M, Rajerison H, Guerard F, et al.Contribution of[64cu]-atsm pet in molecular imaging of tumour hypoxia compared to classical[¹⁸f]-miso-a selected review[J].Nucl Med Rev Cent East Eur, 2011, 14(2):90-95.DOI:10.5603/NMR.2011.00022.

[7]

Marcu LG, Harriss-Phillips WM, Filip SM.Hypoxia in head and neck cancer in theory and practice: A pet-based imaging approach[J/OL].Comput Math Methods Med, 2014, 2014: 624642[2015-09-09].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158154.DOI:10.1155/2014/624642.

[8]

Garcia C, Flamen P.Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era[J].Curr Opin Oncol, 2008, 20(3):275-279.DOI:10.1097/CCO.0b013e3282faa0cb.

[9]

Kumar P, Ohkura K, Beiki D, et al.Synthesis of 1-beta-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole(beta-IAZA):A novel marker of tissue hypoxia[J].Chem Pharm Bull(Tokyo), 2003, 51(4):399-403.DOI:10.1248/cpb.51.399.

[10]

Souvatzoglou M, Grosu AL, Röper B, et al.Tumour hypoxia imaging with[¹⁸F]FAZA PET in head and neck cancer patients:a pilot study[J].Eur J Nucl Med Mol Imaging, 2007, 34(10):1566-1575.DOI:10.1007/s00259-007-0424-3.

[11]

Thomlinson RH, Gray LH.The histological structure of some human lung cancers and the possible implications for radiotherapy[J].Br J Cancer, 1955, 9(4):539-549.

[12]

Overgaard J, Hansen HS, Overgaard M, et al.A randomized double-blind phase Ⅲ study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma.Results of the Danish Head and Neck Cancer Study(DAHANCA)Protocol 5-85[J].Radiother Oncol, 1998, 46(2):135-146.DOI:10.1016/S0167-8140(97)00220-X.

[13]

Abolmaali N, Haase R, Koch A, et al.Two or four hour[¹⁸F]FMISO-PET in HNSCC.When is the contrast best?[J].Nuklearmedizin, 2011, 50(1):22-27.DOI:10.3413/nukmed-00328-10-07.

[14]

Kikuchi M, Yamane T, Shinohara S, et al.¹⁸F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma[J].Ann Nucl Med, 2011, 25(9):625-633.DOI:10.1007/s12149-011-0508-9.

[15]

Yamane T, Kikuchi M, Shinohara S, et al.Reduction of[¹⁸F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma[J].Mol Imaging Biol, 2011, 13(2):227-231.DOI:10.1007/s11307-010-0365-2.

[16]

Sato J, Kitagawa Y, Yamazaki Y, et al.¹⁸F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma[J].J Nucl Med, 2013, 54(7):1060-1065.DOI:10.2967/jnumed.112.114355.

[17]

Okamoto S, Shiga T, Uchiyama Y, et al.Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer[J].Ann Nucl Med, 2014, 28(2):81-87.DOI:10.1007/s12149-013-0781-x.

[18]

Mortensen LS, Buus S, Nordsmark M, et al.Identifying hypoxia in human tumors:A correlation study between ¹⁸F-FMISO PET and the Eppendorf oxygen-sensitive electrode[J].Acta Oncol, 2010, 49(7):934-940.DOI:10.3109/0284186X.2010.516274.

[19]

Mortensen LS, Johansen J, Kallehauge J, et al.Faza PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy:results from the DAHANCA 24 trial[J].Radiother Oncol, 2012, 105(1):14-20.DOI:10.1016/j.radonc.2012.09.015.

[20]

Minagawa Y, Shizukuishi K, Koike I, et al.Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer:a pilot study[J].Ann Nucl Med, 2011, 25(5):339-345.DOI:10.1007/s12149-011-0471-5.

[21]

Vera P, Bohn P, Edet-Sanson A, et al.Simultaneous positron emission tomography(PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose(FDG), proliferation with ¹⁸F-fluoro-thymidine(FLT), and hypoxia with 18fluoro-misonidazole(F-miso) before and during radiotherapy in patients with non-small-cell lung cancer(NSCLC):a pilot study[J].Radiother Oncol, 2011, 98(1):109-116.DOI:10.1016/j.radonc.2010.10.011.

[22]

Thureau S, Chaumet-Riffaud P, Modzelewski R, et al.Interobserver agreement of qualitative analysis and tumor delineation of ¹⁸F-fluoromisonidazole and 3'-deoxy-3'-¹⁸F-fluorothymidine PET images in lung cancer[J].J Nucl Med, 2013, 54(9):1543-1550.DOI:10.2967/jnumed.112.118083.

[23]

Bollineni VR, Kerner GS, Pruim J, et al.PET imaging of tumor hypoxia using ¹⁸F-fluoroazomycin arabinoside in stage Ⅲ-IV non-small cell lung cancer patients[J].J Nucl Med, 2013, 54(8):1175-1180.DOI:10.2967/jnumed.112.115014.

[24]

Trinkaus ME, Blum R, Rischin D, et al.Imaging of hypoxia with ¹⁸F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy[J].J Med Imaging Radiat Oncol, 2013, 57(4):475-481.DOI:10.1111/1754-9485.12086.

[25]

Hu M, Xing L, Mu D, et al.Hypoxia imaging with ¹⁸F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer[J].Clin Nucl Med, 2013, 38(8):591-596.DOI:10.1097/RLU.0b013e318279fd3d.

[26]

Li L, Hu M, Zhu H, et al.Comparison of ¹⁸F-Fluoroerythronitroimidazole and 18f-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer[J].Clin Lung Cancer, 2010, 11(5):335-340.DOI:10.3816/CLC.2010.n.042.

[27]

Zegers CM, Van Elmpt W, Wierts R, et al.Hypoxia imaging with[¹⁸F]HX4 PET in NSCLC patients:defining optimal imaging parameters[J].Radiother Oncol, 2013, 109(1):58-64.DOI:10.1016/j.radonc.2013.08.031.

[28]

Shibahara I, Kumabe T, Kanamori M, et al.Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[¹⁸F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new ¹⁸F-labeled 2-nitroimidazole analog[J].J Neurosurg, 2010, 113(2):358-368.DOI:10.3171/2009.10.JNS09510.

[29]

Beppu T, Terasaki K, Sasaki T, et al.Standardized uptake value in high uptake area on positron emission tomography with ¹⁸F-FRP170 as a hypoxic cell tracer correlates with intratumoral Oxygen pressure in glioblastoma[J].Mol Imaging Biol, 2014, 16(1):127-135.DOI:10.1007/s11307-013-0670-7.

[30]

Schuetz M, Schmid MP, Pötter R, et al.Evaluating repetitive ¹⁸F-fluoroazomycin-arabinoside(¹⁸FAZA)PET in the setting of MRI guided adaptive radiotherapy in cervical cancer[J].Acta Oncol, 2010, 49(7):941-947.DOI:10.3109/0284186X.2010.510145.

[31]

Vercellino L, Groheux D, Thoury A, et al.Hypoxia imaging of uterine cervix carcinoma with ¹⁸F-FETNIM PET/CT[J].Clin Nucl Med, 2012, 37(11):1065-1068.DOI:10.1097/RLU.0b013e3182638e7e.

[32]

Cheng J, Lei L, Xu J, et al.¹⁸F-fluoromisonidazole PET/CT:a potential tool for predicting primary endocrine therapy resistance in breast cancer[J].J Nucl Med, 2013, 54(3):333-340.DOI:10.2967/jnumed.112.111963.

[33]

Segard T, Robins PD, Yusoff IF, et al.Detection of hypoxia with ¹⁸F-fluoromisonidazole(¹⁸F-FMISO)PET/CT in suspected or proven pancreatic cancer[J].Clin Nucl Med, 2013, 38(1):1-6.DOI:10.1097/RLU.0b013e3182708777.

[34]

Hugonnet F, Fournier L, Medioni J, et al.Metastatic renal cell carcinoma:relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response:an ¹⁸F-fluoromisonidazole PET/CT study[J].J Nucl Med, 2011, 52(7):1048-1055.DOI:10.2967/jnumed.110.084517.

[35]

Havelund BM, Holdgaard PC, Rafaelsen SR, et al.Tumour hypoxia imaging with ¹⁸F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer[J].Nucl Med Commun, 2013, 34(2):155-161.DOI:10.1097/MNM.0b013e32835bd5bc.

[36]

Yue J, Yang Y, Cabrera AR, et al.Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma:a pilot clinical study[J].Dis Esophagus, 2012, 25(1):54-61.DOI:10.1111/j.1442-2050.2011.01209.x.

[37]

Staffurth J, Radiotherapy Development Board.A review of the clinical evidence for intensity-modulated radiotherapy[J].Clin Oncol(R Coll Radiol), 2010, 22(8):643-657.DOI:10.1016/j.clon.2010.06.013.

[38]

Welsh L, Panek R, McQuaid D, et al.Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer:the INSIGHT study[J].Radiat Oncol, 2015, 10:112.DOI:10.1186/s13014-015-0415-7.

[39]

Fleckenstein J, Kremp K, Kremp S, et al.IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning[J/OL].Strahlenther Onkol, 2015[2015-09-09].http://link.springer.com/article/10.1007%2Fs00066-015-0900-9. [published online ahead of print Oct 5, 2015].DOI: 10.1007/s00066-015-0900-9.

[40]

Maier FC, Kneilling M, Reischl G, et al.Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using[¹⁸F]-fluoro-azomycinarabino-furanoside([¹⁸F]FAZA)[J/OL].Radiat Oncol, 2011, 6: 165[2015-09-09].http://www.ro-journal.com/content/6/1/165.DOI:10.1186/1748-717X-6-165.

[41]

Cheng Y, Cheng H, Jiang C, et al.Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy[J/OL].Nat Commun, 2015, 6: 8785[2015-09-09].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659941.DOI:10.1038/ncomms9785.

[42]

Simpson JR, Bauer M, Perez CA, et al.Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer:Report of an rtog prospective randomized trial[J].Int J Radiat Oncol Biol Phys, 1989, 16(6):1483-1491.DOI:10.1016/0360-3016(89)90953-X.

[43]

Hassan Metwally MA, Ali R, Kuddu M, et al.IAEA-HypoX.A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma[J].Radiother Oncol, 2015, 116(1):15-20.DOI:10.1016/j.radonc.2015.04.005.

[44]

Zagorevskii D, Song M, Breneman C, et al.A mass spectrometry study of tirapazamine and its metabolites.insights into the mechanism of metabolic transformations and the characterization of reaction intermediates[J].J Am Soc Mass Spectrom, 2003, 14(8):881-892.DOI:10.1016/S1044-0305(03)00334-9.

[45]

von Pawel J, von Roemeling R, Gatzemeier U, et al.Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer:A report of the international CATAPULT I study group.Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors[J].J Clin Oncol, 2000, 18(6):1351-1359.

[46]

Rischin D, Peters L, Fisher R, et al.Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer:a randomized phase Ⅱ trial of the Trans-Tasman Radiation Oncology Group(TROG 98.02)[J].J Clin Oncol, 2005, 23(1):79-87.DOI:10.1200/JCO.2005.01.072.